Mesalazine has structural similarities to aspirin and phenacetin and is nephrotoxic when given intravenously in high doses to rats. A number of cases of nephrotoxicity has been reported recently in patients taking oral mesalazine. Sensitive indicators of renal function in a group of patients maintained on long term, delayed release mesalazine and a comparable group on sulphasalazine have been studied. Sixty two patients (32 men, aged 28-82 years) with quiescent colitis were studied. Thirty four had been maintained on delayed release mesalazine 1-6 (0.8-2.4) g/day for 2-9 (0.5469) years and 28 on sulphasalazine 2 (2-3) g/day. Groups were comparable for age, sex, disease duration, and disease extent. Renal function was assessed by: urine microscopy; creatinine clearance; the urinary excretion of two markers of glomerular toxicity, albumin and transferrin; and the urinary excretion for two markers of tubular toxicity, N-acetyl-P-D-glucosaminidase (NAG) and almicroglobulin. There were no significant differences in renal function between the two treatment groups. Furthermore, no correlations were found between measures of renal function and either cumulative mesalazine dose or mesalazine treatment duration. In this study, long term maintenance treatment with delayed release mesalazine was no more nephrotoxic than continued treatment with sulphasalazine. (Gut 1992; 33: 1348-1352 The effect of mesalazine treatment on renal function has been a particular concern as mesalazine has structural similarities to aspirin and phenacetin, both of which have been implicated in analgesic nephropathy.3 Chronic sulphasalazine treatment does not seem to be nephrotoxic but the systemic absorption of 5-ASA from sulphasalazine is relatively low.4 Delayed release mesalazine formulations release their contents rapidly in the distal small intestine and proximal colon. Plasma concentrations of 5-ASA may therefore be higher in patients taking delayed release mesalazine than in patients taking equivalent doses of sulphasalazine.' In addition, freedom from sulphapyridine related side effects allows high dose treatment, further increasing the potential for dose related nephrotoxicity. We have therefore studied sensitive indicators of renal function in patients maintained on long term, delayed release mesalazine and a comparable group maintained on sulphasalazine.
Recent insights into the pharmacology and component properties of sulphasalazine have led to the development of a new generation of drugs based on mesalazine (5-aminosalicylic acid, 5-ASA). These agents seem as effective as sulphasalazine in the treatment of patients with ulcerative colitis, and in the short term are less toxic.' However, considerations of long term safety are also important as lifelong maintenance treatment is usually recommended. 2 The effect of mesalazine treatment on renal function has been a particular concern as mesalazine has structural similarities to aspirin and phenacetin, both of which have been implicated in analgesic nephropathy.3 Chronic sulphasalazine treatment does not seem to be nephrotoxic but the systemic absorption of 5-ASA from sulphasalazine is relatively low. 4 Delayed release mesalazine formulations release their contents rapidly in the distal small intestine and proximal colon. Plasma concentrations of 5-ASA may therefore be higher in patients taking delayed release mesalazine than in patients taking equivalent doses of sulphasalazine.' In addition, freedom from sulphapyridine related side effects allows high dose treatment, further increasing the potential for dose related nephrotoxicity. We have therefore studied sensitive indicators of renal function in patients maintained on long term, delayed release mesalazine and a comparable group maintained on sulphasalazine.
Methods PATIENT SELECTION AND ASSESSMENT
Patients were selected from a computerised database of 222 patients with chronic ulcerative colitis attending Leigh Infirmary. Of these, 44 had been taking delayed release mesalazine as the sole maintenance treatment for at least six months. For each patient taking mesalazine a computer matched patient taking sulphasalazine was also selected. All pairs were matched for age. (within five years), sex, disease duration (within five years), and disease extent.
Patients were invited to participate by letter and those who consented attended for outpatient review. Patients with symptoms of active colitis in the four weeks before attendance and those with a history of diabetes, hypertension, renal disease, or chronic analgesic ingestion were excluded. A detailed drug history was taken to confirm the type, dose, and duration of maintenance medication.
At the time of clinic attendance patients were asked to provide a freshly voided sample of urine for microscopy and to return with a timed urine collection for measurement of: (i) creatinine clearance; (ii) two markers of glomerular toxicity, albumin and transferrin excretion67; and (iii) two markers of tubular toxicity, a,
To overcome the problems of collecting a 24 hour urine specimen, an overnight collection was made.'0 This had the added advantage ofcontrolling for circadian variations in creatinine clearance" and minimised the effects of postural fluctuations in urinary protein excretion. '2 Patients were asked to empty their bladder before going to bed, noting the precise time and discarding the urine. Urine passed through the night was saved and on rising the bladder was again emptied, the urine saved, and the exact time noted. Patients were asked to return the collection at 9 am the same morning, at which time a 10 ml blood sample was taken. Aliquots of urine and plasma were stored at -20°C before analysis.
In order to establish appropriate normal values for overnight creatinine clearance and marker excretion, 50 age matched healthy volunteers were studied using an identical protocol.
Plasma and urinary creatinine concentrations were measured using the Jaffe reaction. '3 Urinary albumin concentrations were measured by immunoturbidimetry. In brief, a 25 ,ul urine sample was added to 250 p.1 of rabbit antiserum to human albumin (Dakopatts, DK-2600) in buffer. The change in absorbance at 340 nm was measured between 0.5 and 100 seconds and results were derived from absorbance changes produced by eight standard solutions (American Hospital Supply, UK). The range of the assay was 3 to 180 mg/l and between and within batch coefficients of variation were 5.0 and 2.7% respectively. '4 Transferrin concentrations were determined by enzyme immunoassay. 15 Results are shown as median and range. *Duration and dose of sulphasalazine treatment before mesalazine treatment.
unless otherwise stated. Between treatment comparisons were made using signed rank tests and correlations were sought using Spearman's rank correlation test.
Results
Of the 88 patients invited to participate, 62 fulfilled the inclusion criteria and agreed to the study. Thirty four patients had been maintained on delayed release mesalazine for a minimum of six months and 28 had been maintained on long term sulphasalazine. The two groups were comparable for age, sex, disease duration, and disease extent (Table) . Patients treated with mesalazine had taken the drug for 2.9 (0.5-6 9) years at a daily dose of 1[6 (0 8-2 4) g daily; the total cumulative mesalazine Urine microscopy was unremarkable in all cases. Creatinine clearance values varied widely but did not differ significantly between the two treatment groups (mesalazine=90 (47-172) ml/ minm sulphasalazine=85 (48-153) ml/min) or between the treatment groups and the healthy volunteers (healthy volunteers=79 (34-180 ml/ min) (Fig 1) . A negative correlation between creatinine clearance and age was apparent in all three groups (mesalazine: r=-0-44, p<001; sulphasalazine: r= -0-36, p<0O05; healthy volunteers: r=-0-47, p<001). No significant correlations were apparent between creatinine clearance and either duration ofmesalazine treatment or cumulative mesalazine dose.
The results of urinary albumin and transferrin excretion are shown in Figure 2 . All results are expressed as marker/creatinine concentration ratios in order to standardise for differences in timing of the urine collection. '6 In the healthy volunteers the albumin/creatinine ratio was 0-60 (0-3-3) mg/mmol and the transferrin/creatinine ratio was 17.2 (2.0-161) [ig/mmol. (The upper limit of normal for each measure was set at the 95th centile). There were no significant differences between the two treatment groups (albumin/creatinine ratio: mesalazine=0091 (0.23-4 55) mg/mmol, sulphasalazine=0.84 (0.24-7.95) mg/mmol; transferrin/creatinine ratio: mesalazine=7.4 [tg/mmol, sulphasalazine= 17-6 (1-229) [ig/mmol) or between the treatment groups and healthy volunteers. Four patients had albumin/ creatinine ratios above the 95th centile (two mesalazine, two sulphasalazine) and four patients had mildly raised transferrin/creatinine ratios (one mesalazine, three sulphasalasine). Albumin/creatinine ratios were positively correlated with transferrin/creatinine ratios in both treatment groups (mesalazine r=0-44, p<001; sulphasalazine r=0-38, p<0 05) but neither correlated with the duration of mesalazine treatment or cumulative mesalazine dose. Figure 3 shows the results of e,-microglobulin/ creatinine and NAG/creatinine concentration ratios. In healthy volunteers the clmicroglobulin/creatinine and NAG/creatinine ratios were 277 [ig/mmol and 240
(1-755) mU/mmol respectively. No significant differences were found between the two treatment groups (a1-microglobulin/creatinine ratio: mesalazine= 132 (3-1070) ,tg/mmol, sulphasalazine= 193 [ig/mmol; NAG/creatinine ratio: mesalazine= 187 (49-1360) mU/mmol, sulphasalazine=202 (64-650) mU/mmol) or between the treatment groups and healthy volunteers. Five patients had raised a -microglobulin ratios (one mesalazine, four sulphasalazine) and four patients had high NAG ratios (two mesalazine, two sulphasalazine). a1-microglobulin/creatinine ratios correlated with NAG/ creatinine ratios in both treatment groups (mesalazine r=0-56, p<001; sulphasalazine r=0-64, p<001) but neither correlated with the duration of mesalazine treatment or cumulative mesalazine dose. Studies of the effect of mesalazine function are relatively few. In the rat, X single doses of intravenous mesalazii acute tubular and papillary necrosis.3 H oral mesalazine does not seem to be nep in rats when given for four weeks27 but and dogs develop renal papillary necro fed high dose mesalazine for 6 to 12 mor After oral administration, mesalazine sively acetylated such that N-acetyl-5-A predominant form found in both pla urine.S 29 The nephrotoxicity of N-acety is therefore of interest, particularly a structural changes to the aspirin and ph molecules are known to influence toxicity.30 Furthermore, the plasma 5-ASA to N-acetyl-5-ASA varies som( patients maintained on the different ml formulations5 29 and this has led some tc differences in nephrotoxic potential. 3 evidence to suggest dose dependent nephrotoxicity and in the present study long term maintenance treatment with delayed release mesalazine was no more nephrotoxic than continued treatment with sulphasalazine.
Discussion

